A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients

Kidney International

Volumn 95, Issue 4, 2019, Pages 983-991

  Hammer, Fabian ^a,b   Malzahn, Uwe ^a   Donhauser, Julian ^c   Betz, Christoph ^d   Schneider, Markus P ^e   Grupp, Clemens ^f   Pollak, Nils ^a   Störk, Stefan ^a   Wanner, Christoph ^a   Krane, Vera ^a   Berweck, Susanne ^f   Biggar, Patrick ^f   Blaser, Christoph ^f   Bochannek, Thomas ^f   Breunig, Frank ^f   Brunner, Michael ^f   Büschges Seraphin, Beatrix ^f   Büttner, Stefan ^f   Cakmak, Ahmet ^f   Döltz, Thomas ^f   Dörken, Mara ^f   Eckardt, Kai Uwe ^f   Fink, Heribert ^f   Fischer, Stefan ^f   Freisinger, Wolfgang ^f   Freiwald, Tilo ^f   Gebhardt, Julian ^f   Geiger, Helmut ^f   Götz, Rüdiger ^f   Goßmann, Jan ^f   Hammerstingl, Renate ^f   Harazny, Joanna ^f   Heckel, Michael ^f   Heyd Schramm, Andrea ^f   Hoyer, Joachim ^f   Janka, Rolf ^f   Jung, Oliver ^f   Ketteler, Markus ^f   Klaeffling, Christina ^f   Kleinert, Claudius ^f   Kleinert, Marianne ^f   Klingbeil, Arnfried ^f   Klink, Thorsten ^f   Koch, Benjamin Florian ^f   Kosowski, Judith ^f   Leidig, Michael ^f   Lutz, Jens ^f   Marwan, Mohamed ^f   Moritz, Maria ^f   Moye, Brigitte ^f   Naujoks, Holger ^f   Netzer, Kai Olaf ^f   Raff, Ulrike ^f   Reichert, Clemens ^f   Reimer, Imke ^f   Ribel, Jurij ^f   Richter, Sophie ^f   Ritter, Christian ^f   Rudolf, Sarah ^f   Schamberger, Beate ^f   Schmid, Michael ^f   Schmiedeke, Thomas ^f   Schmitt, Andreas ^f   Schneider, Heike ^f   Schneider, Reinhard ^f   Schneuzer, Cord ^f   Schöffauer, Markus ^f   Schramm, Lothar ^f   Schütterle, Sabine ^f   Schwedler, Susanne ^f   Sobkowiak, Ewelina ^f   Sollinger, Daniel ^f   Strutz, Frank ^f   Toncar, Sebastian ^f   Vasiljuk, Vladimir ^f   Vogl, Thomas ^f   Walther, Thorsten ^f   Weinmann Menke, Julia ^f   Wirth, Bettina ^f   Witsch, Hendrick ^f   Würmell, Paul ^f   Zeltner, Raoul ^f   Zimmermann, Josef ^f   more..

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f University Hospital Erlangen ^*

Author keywords

blood pressure; hemodialysis; left ventricular mass index; potassium; spironolactone

Indexed keywords

PLACEBO; POTASSIUM; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

ADULT; ALL CAUSE MORTALITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEW YORK HEART ASSOCIATION CLASS; POTASSIUM BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIX MINUTE WALK TEST; SYSTOLIC BLOOD PRESSURE; URINE VOLUME; AGED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE; HEART VENTRICLE REMODELING; HEMODIALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

AGED; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPERKALEMIA; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PLACEBOS; RENAL DIALYSIS; SPIRONOLACTONE; STROKE VOLUME; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 85062702483     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2018.11.025     Document Type: Article

References (35)

1. Pippias, M., Jager, K.J., Kramer, A., et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. Nephrol Dial Transplant 31 (2016), 831–841.
2. Wanner, C., Krane, V., Marz, W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 (2005), 238–248.
3. Wheeler, D.C., London, G.M., Parfrey, P.S., et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J Am Heart Assoc, 3, 2014, e001363.
4. Middleton, R.J., Parfrey, P.S., Foley, R.N., Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 12 (2001), 1079–1084.
5. Foley, R.N., Parfrey, P.S., Harnett, J.D., et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47 (1995), 186–192.
6. Di Lullo, L., Gorini, A., Russo, D., et al. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment. Cardiorenal Med 5 (2015), 254–266.
7. Makar, M.S., Pun, P.H., Sudden cardiac death among hemodialysis patients. Am J Kidney Dis 69 (2017), 684–695.
8. Mostovaya, I.M., Bots, M.L., van den Dorpel, M.A., et al. Left ventricular mass in dialysis patients, determinants and relation with outcome. Results from the COnvective TRansport STudy (CONTRAST). PLoS One, 9, 2014, e84587.
9. Zoccali, C., Benedetto, F.A., Mallamaci, F., et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 65 (2004), 1492–1498.
10. Paoletti, E., Specchia, C., Di Maio, G., et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 19 (2004), 1829–1834.
11. London, G.M., Pannier, B., Guerin, A.P., et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12 (2001), 2759–2767.
12. Paoletti, E., Bellino, D., Signori, A., et al. Regression of asymptomatic cardiomyopathy and clinical outcome of renal transplant recipients: a long-term prospective cohort study. Nephrol Dial Transplant 31 (2016), 1168–1174.
13. Quach, K., Lvtvyn, L., Baigent, C., et al. The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis. Am J Kidney Dis 68 (2016), 591–598.
14. McGill, R.L., Biederman, R.W., Getts, R.T., et al. Cardiac magnetic resonance imaging in hemodialysis patients. J Nephrol 22 (2009), 367–372.
15. Taheri, S., Mortazavi, M., Pourmoghadas, A., et al. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 23 (2012), 507–512.
16. Flevari, P., Kalogeropoulou, S., Drakou, A., et al. Spironolactone improves endothelial and cardiac autonomic function in nonheart failure hemodialysis patients. J Hypertens 31 (2013), 1239–1244.
17. Feniman-De-Stefano, G.M., Zanati-Basan, S.G., De Stefano, L.M., et al. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. Ther Adv Cardiovasc Dis 9 (2015), 158–167.
18. Ito, Y., Mizuno, M., Suzuki, Y., et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 25 (2014), 1094–1102.
19. Lin, C., Zhang, Q., Zhang, H., et al. Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebo-controlled study. J Clin Hypertens (Greenwich) 18 (2016), 121–128.
20. Glassock, R.J., Pecoits-Filho, R., Barberato, S.H., Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 4:Suppl 1 (2009), S79–S91.
21. Edwards, N.C., Steeds, R.P., Stewart, P.M., et al. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 54 (2009), 505–512.
22. Pitt, B., Reichek, N., Willenbrock, R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108 (2003), 1831–1838.
23. Schneider, A., Schwab, J., Karg, M.V., et al. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension. J Hypertens 35 (2017), 1086–1092.
24. Matsumoto, Y., Mori, Y., Kageyama, S., et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 63 (2014), 528–536.
25. Vukusich, A., Kunstmann, S., Varela, C., et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 5 (2010), 1380–1387.
26. Walsh, M., Manns, B., Garg, A.X., et al. The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial. Clin J Am Soc Nephrol 10 (2015), 1602–1608.
27. Gross, E., Rothstein, M., Dombek, S., et al. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 46 (2005), 94–101.
28. Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999), 709–717.
29. Lu, R., Zhang, Y., Zhu, X., et al. Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis. Int Urol Nephrol 48 (2016), 1499–1509.
30. Mathew, A.T., Fishbane, S., Obi, Y., et al. Preservation of residual kidney function in hemodialysis patients: reviving an old concept. Kidney Int 90 (2016), 262–271.
31. Hammer, F., Krane, V., Stork, S., et al. Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrol Dial Transplant 29 (2014), 400–405.
32. Yeon, S.B., Salton, C.J., Gona, P., et al. Impact of age, sex, and indexation method on MR left ventricular reference values in the Framingham Heart Study offspring cohort. J Magn Reson Imaging 41 (2015), 1038–1045.
33. Landis, J.R., Koch, G.G., The measurement of observer agreement for categorical data. Biometrics 33 (1977), 159–174.
34. Miettinen, O., Nurminen, M., Comparative analysis of two rates. Stat Med 4 (1985), 213–226.
35. ® . 2007, Gilead Sciences Inc, Foster City, CA.